- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: BEAMing.
Displaying page 1 of 1.
EudraCT Number: 2018-004231-72 | Sponsor Protocol Number: IBICCR2018-01 | Start Date*: 2019-06-27 | |||||||||||
Sponsor Name:Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS) | |||||||||||||
Full Title: Randomized study of the detection of RAS / BRAF mutations by BEAMing technology in advance of the radiological diagnosis of progression in patients with metastatic colorectal cancer RAS / BRAF WT a... | |||||||||||||
Medical condition: Median of the progression-free survival of patients with mCRC who maintains the treatment in conventional 1st line, QT + anti-EFGR, versus patients who withdraw anti-EGFR therapy after detection of... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002094-22 | Sponsor Protocol Number: FiHM006 | Start Date*: 2019-01-17 | |||||||||||
Sponsor Name:Fundación de investigación de HM Hospitales | |||||||||||||
Full Title: A Phase II Trial to Assess the Evolution of KRAS Mutation Load by Liquid Biopsy in Patients with Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant NALIRINOX | |||||||||||||
Medical condition: Resectable Pancreatic Ductal Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000311-25 | Sponsor Protocol Number: BAY86-9766/16553 | Start Date*: 2013-10-17 |
Sponsor Name:Bayer Healthcare AG | ||
Full Title: A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma (HCC) | ||
Medical condition: KRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) BE (Completed) AT (Completed) GB (Completed) DE (Completed) HU (Completed) ES (Completed) IT (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000241-39 | Sponsor Protocol Number: BAY86-9766/16728 | Start Date*: 2013-07-26 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line treatment in patients with RAS mutant Hepato... | ||
Medical condition: KRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) IT (Completed) HU (Completed) ES (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
